Page 108 - Read Online

Correnti et al. Hepatoma Res 2018;4:69 I http://dx.doi.org/10.20517/2394-5079.2018.96 Page 13 of 15

104. Zhang Y, Zheng L, Ding Y, Li Q, Wang R, et al. MiR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway
in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2015;92:1132-40.
105. Chiba T, Suzuki E, Yuki K, Zen Y, Oshima M, et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38
MAPK pathway-dependent and -independent manners. PLoS One 2014;9:e84807.
106. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, et al. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting
RAS/RAF/MAPK and WNT/beta-catenin pathways. Anticancer Res 2014;34:1709-13.
107. Zhang L, Zhang L, Li H, Ge C, Zhao F, et al. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation
loop with CD133 in HCC via Erk1/2 phosphorylation. Sci Rep 2016;6:27426.
108. Ding K, Liao Y, Gong D, Zhao X, Ji W. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+
cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun 2018;502:194-201.
109. Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, et al. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/
Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol 2010;177:141-52.
110. Chan SL, Chan AW, Yeo W. Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opin Ther Targets
2015;19:973-83.
111. Chan LH, Luk ST, Ma S. Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives. Mol Cells
2015;38:202-9.
112. Andersen JB, Thorgeirsson SS. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Future
Medicine (Hepatic Oncology) 2014;1:143-57.
113. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-
renewal. J Clin Invest 2014;124:553-63.
114. Cook AM, Li L, Ho Y, Lin A, Stein A, et al. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of
human acute myeloid leukemia stem cells. Blood 2014;123:2826-37.
115. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem
cells. Stem Cells 2009;27:2383-92.
116. Liu RY, Zeng Y, Lei Z, Wang L, Yang H, et al. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in
lung cancer cells. Int J Oncol 2014;44:1643-51.
117. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer
invasion and metastasis. J Clin Invest 2014;124:1853-67.
118. Wang X, Sun W, Shen W, Xia M, Chen C, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J
Hepatol 2016;64:1283-94.
119. Mitra A, Yan J, Xia X, Zhou S, Chen J, et al. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition(+)
metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient beta2-spectrin(+/-) mice. Hepatology
2017;65:1222-36.
120. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J
Gastroenterol 2009;15:4240-62.
121. Correnti M, Raggi C. Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer.
Oncotarget 2017;8:7094-115.
122. Qiu L, Li H, Fu S, Chen X, Lu L. Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. Oncol Lett
2018;15:2039-48.
123. Chen J, Jin R, Zhao J, Liu J, Ying H, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in
hepatocellular carcinoma. Cancer Lett 2015;367:1-11.
124. Chow AK, Ng L, Lam CS, Wong SK, Wan TM, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with
sorafenib resistance. PLoS One 2013;8:e78675.
125. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and
metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology 2012;143:1641-9 e5.
126. Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S, et al. Cancer stem-like sphere cells induced from de-differentiated
hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer 2014;14:722.
127. Jang JW, Song Y, Kim SH, Kim JS, Kim KM, et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in
hepatocellular carcinoma. Cancer Lett 2017;389:1-10.
128. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014;14:306-21.
129. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell
2008;13:153-66.
130. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MNP, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology
2008;47:919-28.
131. Zhu L, Zhang W, Wang J, Liu R. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma. Tumour
Biol 2015;36:5353-60.
132. Liu S, Li N, Yu X, Xiao X, Cheng K, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and
circulating tumor cells. Gastroenterology 2013;144:1031-41 e10.
133. Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, et al. Transforming growth factor-beta1-induced epithelial-mesenchymal transition generates
ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett 2014;354:320-8.
134. Lee D, Na J, Ryu J, Kim HJ, Nam SH, et al. Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating
capacities of hepatocarcinoma cells. Hepatology 2015;61:1978-97.
135. Nishiyama M, Tsunedomi R, Yoshimura K, Hashimoto N, Matsukuma S, et al. Metastatic ability and the epithelial-mesenchymal transition
in induced cancer stem-like hepatoma cells. Cancer Sci 2018;109:1101-9.